© The Author [2009].
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
Key insights into present and future treatments of anaemia in CKD patients
Servicio de Nefrología, Hospital Universitario Valdecilla, Santander, Spain
Correspondence: Angel L. M. de Francisco, Presidente de la Sociedad Española de Nefrología, Servicio de Nefrología, Hospital Universitario Valdecilla, Santander, Spain. Tel: +34-942-202738; Fax: +34-942-320415; E-mail: martinal@unican.es
Key Words: anaemia management • chronic kidney disease • erythropoiesis-stimulating agents • haemoglobin levels
Received for publication September 19, 2008. Accepted for publication October 21, 2008.
| The first 10% of the full text of this article appears below. |
 |
Introduction |
|---|
The introduction of erythropoiesis-stimulating agents (ESAs) revolutionized the management of anaemia in chronic kidney disease (CKD) patients by providing effective control of haemoglobin (Hb) levels, reducing the need for blood transfusions and improving patient quality of life. The use of ESAs in CKD patients is constantly evolving as new research helps us to better understand how to safely and effectively manage anaemia in these patients.